Navigation Links
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
Date:11/7/2010

NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months. For a third primary endpoint, the rate of DAS28-4(ESR) <2.6, a measure of disease remission, treatment with tasocitinib resulted in a numerically greater, but not statistically significant difference from placebo at three months.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

In ORAL Solo, a similar frequency of adverse events was seen across all treatment groups. Serious adverse events were reported in 4.1 percent of patients. Additionally, decreases in neutrophil count and hemoglobin and an increase in cholesterol occurred by month three. These changes tended to stabilize thereafter. No new safety signals were detected.

"We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib monotherapy in ORAL Solo," said Roy Fleischmann, MD, Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas.  "Further research into additional treatment options for patients with moderately to severely active RA is important, and we look forward to seeing the results of the additional Phase 3 ORAL trials of tasocitinib."

ORAL Sequel (1024), an open label, follow-up Phase 2/3 study,
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
2. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
3. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
5. GREENGUARDs First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently
6. CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
9. PAREXEL Reports First Quarter Fiscal Year 2011 Financial Results
10. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
11. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street Health ... an initial seed round of funding. ... led by a series of individual investors, the majority ... participated in the initial round are; Houston Cardiology ... Center Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... BURLINGTON, Mass. , Sept. 18, 2014  Decision ... launched anti-vascular endothelial growth factor (VEGF) agent for wet ... and Medicare Advantage plans as Genentech,s Lucentis, which is ... although surveyed managed care organization (MCO) directors do not ... Eylea is slightly more likely than Lucentis to be ...
(Date:9/18/2014)... , Sept. 18, 2014  A $3 million grant ... the University of Michigan to establish a national center ... Glenn Center for Aging Research at U-M will focus ... can slow the effects of aging and postpone diseases ... aging that can help develop medications that may help ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
... April 25, 2011 The ophthalmic therapeutics company Xcovery ... and CEO, and Dr. Ken Mandell, President and COO, ... Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale ... of a Serial Entrepreneur recounts his repeated success ...
... April 25, 2011 The 2010 Pharmacy Today ... American Pharmacists Association , reveals pharmacists believe that ... was recommended by their pharmacist, 92% of pharmacists walk ... a product selection and the average patient consult takes ...
Cached Medicine Technology:Xcovery Vision Founders to Speak at ARVO 2011 2Pharmacists Offer Guidance on Top Over-The-Counter Medications 2Pharmacists Offer Guidance on Top Over-The-Counter Medications 3
(Date:9/18/2014)... "Medical staff need better ways to provide quick ... privacy," said one of two inventors from Hialeah, Fla. ... supply caregivers with the equipment they need to do ... The Helper to make it easier to reposition a ... his or her side. It also securely stabilizes the ...
(Date:9/18/2014)... 2014 It’s been just a few short ... pending bunion splint to website visitors, but already the response ... was absolutely delighted. It is perfect and I find it ... them. THANK YOU FOR LISTENING!!!" Another user compared the ... hole used to slip to the end of my toe. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Companies in ... refine carbon dioxide, selling it to downstream industries in ... for carbon dioxide are food and beverage manufacturers. Food ... as fruits, vegetables or pizzas. The gas is also ... use the compound to carbonate soft drinks, beer and ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... waiting times, patients seeking care at larger urban hospitals are ... those seen at smaller or more rural facilities, new research ... provide timely emergency care varies dramatically across hospitals in the ... research, Dr. Renee Hsia, an associate professor at the University ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Daily supplements of ... against the development of age-related cataracts among men, a ... that one or both could help prevent cataracts. To ... Hospital and Harvard Medical School in Boston, and his ... selenium and vitamin E. The trial was initially designed ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2
... MONDAY, Oct. 17 (HealthDay News) -- For years, nutritionists ... eat." Now, new research suggests this adage might even ... observation stems from a pair of studies slated for presentation ... in Orlando, Fla., both of which highlight an apparent linkage ...
... MASS. October 17, 2011 The Institute for ... announced Sharon K. Inouye, M.D., M.P.H., has been elected ... independent, nonprofit organization that works outside of government to ... the public. Inouye is the Director of the ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay News) ... candy and some medications, teachers are almost as likely to ... by two enterprising elementary schoolers. Casey Gittelman, who,s ... a special medicine cabinet filled with medicine and candies to ...
... is available in French and Spanish . ... than other women. Furthermore, the likelihood of developing breast cancer is ... of the main conclusions drawn in an article recently published in ... Granada research group CTS 367, coordinated by the Nursery Department professor ...
... Jenifer Goodwin HealthDay Reporter , SATURDAY, Oct. 15 ... hospital emergency departments don,t believe their weight poses a risk ... them otherwise, a new study finds. Researchers asked 450 ... at Shands at the University of Florida two questions: Do ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay News) -- Is ... so, says a new study that finds a link between ... However, the research doesn,t confirm that exposure to trash-talking ... explain why non-aggressive cussing might be a bad thing. And ...
Cached Medicine News:Health News:Healthier Diet, Stronger Sperm? 2Health News:Healthier Diet, Stronger Sperm? 3Health News:Hebrew SeniorLife's Dr. Sharon K. Inouye elected to Institute of Medicine 2Health News:It's Easy to Mistake Medicine for Candy 2Health News:It's Easy to Mistake Medicine for Candy 3Health News:Obese women have higher risk of suffering breast cancer 2Health News:Many Don't Believe Their Obesity is Unhealthy: Study 2Health News:Many Don't Believe Their Obesity is Unhealthy: Study 3Health News:Many Don't Believe Their Obesity is Unhealthy: Study 4Health News:Profanity on TV Linked to Foul-Mouthed Kids 2
... for Candida albicans in only five ... two enzyme color reactions to produce ... read. AlbiQuicktm is performed on a ... Incubation time is only five minutes ...
... for small and large multi-specialty provider networks. ... check-out. Review the complete Patient History, from ... labs and charts all by one click ... immediately. Communicate electronically with the referring physicians ...
... meridianEMR is a revolutionary "blended model EMR ... medical records in your office and on-line ... of physicians and software engineers, meridianEMR combines ... create a highly modular medical EMR that ...
... an Automated Digital Cell Morphology and Informatics ... and transmission of White & Red Blood ... blood smears can be loaded at once, ... 60 per hour depending on the tests ...
Medicine Products: